In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Testing Drugs Against New Targets: Like Playing Blind Man's Bluff?

Executive Summary

As companies move into development of drugs against novel targets, including a host of genomically derived drugs, they are assuming a new kind of target risk. The heightened risk exists largely because the targets revealed by genomics techniques for the most part have not been validated by linking them empirically to the initiation or maintenance of a disease state, nor through the use of biomarkers during clinical development. Stumbles in the pursuit of drugs against EGFR are symptomatic of this new pharma industry problem. In this context, the cancer drugs Herceptin and Gleevec, widely touted as the first examples of rapidly developed, rationally designed molecular medicines, will prove to be much more the exception than the rule. And importantly, the emerging pattern of EGFR drug development suggests that pursuit of novel targets will do little to ameliorate the industry's R&D productivity problem.
Advertisement

Related Content

AstraZeneca's Nuanced View of Drug Development
What Keeps Cancer Drug Developers Awake at Night
AstraZeneca's Nuanced View of Cancer Drug Development
Our Top Ten Items from a Year Most Want to Forget
Genta's Clinical Quest
Big Pharma's Response to R&D Woes: More Early-Stage Compound Deals
Roche Bucks the Trend, with Early-Stage Deals
Gore Partners with Medinol on the Rebound in Global Stent Deal
Pfizer R&D: The Biggest Pharmaceutical Experiment
Pfizer R&D: The Biggest Pharmaceutical Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel